Howard Levy

TL;DR: There was no decrease in mortality between placebo and TNF-α MAb in all infused patients, and in septic shock patients who received T NF- α MAb, a significant reduction in mortality was present 3 days after infusion; however, although a trend toward reduced mortality continued at 28 days following treatment with TTFMAb, the difference in mortality among shock patients treated with placebo or TFB was not significant.

TL;DR: It was found there was no association between therapy with TNFα MAb and increased rapidity in reversal of initial shock or prevention of subsequent shock, and baseline plasma interleukin-6 concentrations were not associated with improvement in survival after TNF α MAb therapy.

TL;DR: The rate of accrual of subjects in the present study was inadequate and the lack of trends supporting the use of intravenous ribavirin suggests that it is probably ineffective in the treatment of HCPS in the cardiopulmonary stage.

TL;DR: There was no difference in aspiration rates between gastrically and transpylorically fed critically ill patients in the intensive care unit, and clinical suspicion of aspiration was insensitive and detected only 60% of isotopically documented aspirations.

TL;DR: Patients who require reintubation have significantly higher preextubation FIo2 and ventilatory requirements than patients who remain extubated, and reintsubation after unplanned extubation should not be considered mandatory.